ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1307

Plasma levels of monounsaturated fatty acids (MUFAs) positively correlate with disease activity in patients with rheumatoid arthritis (RA)

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1325

Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1097

Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1388

Positive predictive value of various diagnostic codes for the classification of primary Sjӧgren’s syndrome

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1519

Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0930

Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis

(0916–0933) Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 0913

Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 1003

Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0998

Preclinical Characterization of a Novel Bi-specific Antibody Targeting IL-23p19 and IL-36R for The Treatment of Autoimmune Diseases

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0906

Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 0914

Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 1316

Predicting mortality of rheumatoid arthritis in China: A nation-wide cohort study

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1648

Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)

(1633–1649) ARP Posters II: ARP Epidemiology & Public Health

10:30AM-12:30PM: Abstract Number: 1352

Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1030

Predictors of Incident Atrial Fibrillation in Rheumatoid Arthritis Patients: A Population Based Cohort Study

(1007–1037) Epidemiology & Public Health Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].